Alt of image

Matt
Eyles

Immediate past president & CEO, America’s Health Insurance Plans (AHIP)

Matthew (Matt) Eyles is the immediate past president & CEO of AHIP, the national association representing health insurance providers, including national and for-profit plans (e.g., CVS Health, Cigna Group, Elevance Health), Blue Cross Blue Shield companies, local and regional plans and companies offering supplemental coverage products. After joining AHIP’s executive leadership in 2015, Matt was appointed president & CEO in 2018 by the AHIP Board of Directors to lead the association’s work to fulfill its mission and vision by expanding access to affordable health care coverage to all Americans through a competitive marketplace. In his five years heading AHIP, Matt revitalized the association’s advocacy, membership, operations and finances before deciding to step down in October 2023.

Matt has over three decades of health care experience in the private sector and government. Before running AHIP, he led teams in diverse roles at Fortune 150 health care companies (Eli Lilly, Wyeth/Pfizer, Coventry/Aetna) – including public policy, government affairs, advocacy and corporate communications with both U.S. and global responsibilities – and in consulting at Avalere where he advised companies and organizations across all healthcare sectors. Matt began his career at the Congressional Budget Office and worked on a range of legislative, budgetary and regulatory policy issues.

Matt was named one of the 100 Most Influential People in Health Care by Modern Healthcare for five consecutive years (2018-2022), a Top Lobbyist by The Hill, a Healthcare Power Player by Business Insider, and one of Washington’s 250 Most Influential People by Washingtonian. Currently, Matt is enjoying pursuing a diverse range of personal and professional interests, including innovative opportunities in health care and finance, health technology and coverage platforms focused on improving affordability, patient and consumer experience and outcomes and in academia.